Literature DB >> 23999685

Use of marginal grafts in deceased donor liver transplant: assessment of early outcomes.

Rajesh Godara1, C Sudeep Naidu, Pankaj P Rao, Sanjay Sharma, Jayant K Banerjee, Anupam Saha, Kapileshwer Vijay.   

Abstract

INTRODUCTION: Orthotopic liver transplantation has become a routinely applied therapy for an expanding group of patients with end-stage liver disease. Shortage of organs has led centers to expand their criteria for the acceptance of marginal donors. There is current debate about the regulation and results of liver transplantation using marginal grafts.
METHODS: The study included data of all patients who received deceased donor liver grafts between March 2007 to December 2011. Patients with acute liver failure, living donor transplantation, split liver transplantation, and retransplantation were excluded. Early allograft dysfunction, primary nonfunction, patient survival, and incidence of surgical complications were measured.
RESULTS: A total of 33 patients were enrolled in this study. There were 20 marginal and 13 nonmarginal grafts. The two groups were well matched regarding age, sex and indication of liver transplantation, model for end-stage liver disease score, technique of transplant, requirement of vascular reconstruction, warm ischemia time, blood loss, mean operative time, etc. In our study, posttransplant peak level of liver enzymes, international normalization ratio, and bilirubin were not statistically significant in the marginal and nonmarginal group. Wound infection occurred in 10 % of marginal compared with 7.7 % of nonmarginal graft recipients (p > 0.05). In the marginal group, the incidences of vascular complications, hepatic artery thrombosis (four), and portal vein thrombosis (one) were not statistically significant compared to the nonmarginal group. Acute rejection was observed in a total of seven patients (21.2 %)-five (25 %) in the marginal group and two (15.4 %) in the nonmarginal graft recipients. Primary nonfunction occurred in three (9.1 %) patients-two (10 %) in the marginal and one (7.7 %) in the nonmarginal group. Average patient survival for the whole group was 91 % at 1 week, 87.8 % at 3 months, and 84.8 % at 6 months.
CONCLUSION: Because organ scarcity persists, additional pressure will build to use a greater proportion of the existing donor pool. The study, although small, clearly indicates that marginal livers can assure a normal early functional recovery after transplantation.

Entities:  

Mesh:

Year:  2013        PMID: 23999685     DOI: 10.1007/s12664-013-0379-1

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  18 in total

1.  Risk factors and predictive indexes of early graft failure in liver transplantation.

Authors:  I R Marino; T E Starzl; L Aldrighetti; C Doria; F Morelli; T J Gayowski; J R Madariaga; H R Doyle
Journal:  Ital J Gastroenterol       Date:  1996-04

2.  Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors.

Authors:  Kim M Olthoff; Laura Kulik; Benjamin Samstein; Mary Kaminski; Michael Abecassis; Jean Emond; Abraham Shaked; Jason D Christie
Journal:  Liver Transpl       Date:  2010-08       Impact factor: 5.799

3.  Impact of donor factors and preservation on function and survival after liver transplantation.

Authors:  R J Ploeg; A M D'Alessandro; R M Hoffmann; D Eckhoff; R Isaacs; S J Knechtle; J D Pirsch; M D Stegall; M Kalayoglu; F O Belzer
Journal:  Transplant Proc       Date:  1993-12       Impact factor: 1.066

Review 4.  Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation.

Authors:  S M Strasberg; T K Howard; E P Molmenti; M Hertl
Journal:  Hepatology       Date:  1994-10       Impact factor: 17.425

5.  A proposal for scoring marginal liver grafts.

Authors:  J Briceño; G Solórzano; C Pera
Journal:  Transpl Int       Date:  2000       Impact factor: 3.782

6.  Early allograft dysfunction after liver transplantation: a definition and predictors of outcome. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.

Authors:  M Deschênes; S H Belle; R A Krom; R K Zetterman; J R Lake
Journal:  Transplantation       Date:  1998-08-15       Impact factor: 4.939

7.  Risk factors for primary dysfunction after liver transplantation--a multivariate analysis.

Authors:  R J Ploeg; A M D'Alessandro; S J Knechtle; M D Stegall; J D Pirsch; R M Hoffmann; T Sasaki; H W Sollinger; F O Belzer; M Kalayoglu
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

8.  The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors.

Authors:  E Mor; G B Klintmalm; T A Gonwa; H Solomon; M J Holman; J F Gibbs; I Watemberg; R M Goldstein; B S Husberg
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939

9.  Marginal grafts increase early mortality in liver transplantation.

Authors:  Telesforo Bacchella; Flávio Henrique Ferreira Galvão; José Luiz Jesus de Almeida; Estela Regina Figueira; Andreza de Moraes; Marcel Cerqueira César Machado
Journal:  Sao Paulo Med J       Date:  2008-05-01       Impact factor: 1.044

10.  Predictive factors of early postoperative graft function in human liver transplantation.

Authors:  F X González; A Rimola; L Grande; M Antolin; J C Garcia-Valdecasas; J Fuster; A M Lacy; E Cugat; J Visa; J Rodés
Journal:  Hepatology       Date:  1994-09       Impact factor: 17.425

View more
  2 in total

1.  Deceased donor liver transplant: Experience from a public sector hospital in India.

Authors:  Viniyendra Pamecha; Deeplaxmi Purushottam Borle; Senthil Kumar; Kishore Gurumoorthy Subramanya Bharathy; Piyush Kumar Sinha; Shridhar Vasantrao Sasturkar; Vibuti Sharma; Chandra Kant Pandey; Shiv Kumar Sarin
Journal:  Indian J Gastroenterol       Date:  2017-11-29

Review 2.  Changing pattern of donor selection criteria in deceased donor liver transplant: a review of literature.

Authors:  Dronacharya Routh; Sudeep Naidu; Sanjay Sharma; Priya Ranjan; Rajesh Godara
Journal:  J Clin Exp Hepatol       Date:  2013-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.